John Cox Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for John Cox.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of John Cox. John Cox is Director in REPLIGEN CORP ($RGEN) and EVP Pharmaceutical Oper & Tech in BIOGEN INC. ($IDPH) and Chief Executive Officer in Bioverativ Inc. ($BIVV) and in Sigilon Therapeutics, Inc. ($SGTX) and Director in Sigilon Therapeutics, Inc. ($SGTX).
Latest Insider Trading Transactions of John Cox
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, IDPH, BIVV, RGEN, SGTX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 28 2021 | SGTX | Sigilon Therapeuti ... | Cox John | Option Exercise | A | 9.97 | 8,888 | 88,613 | 8,888 | ||
| Dec 10 2020 | SGTX | Sigilon Therapeuti ... | Cox John | Director | Option Exercise | C | 0.00 | 4,444 | 0 | 0 | |
| Dec 10 2020 | SGTX | Sigilon Therapeuti ... | Cox John | Director | Buy | C | 0.00 | 4,444 | 0 | 4,444 | 0 to 4.4 K |
| Mar 26 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Sell | S | 96.72 | 1,858 | 179,706 | 923 | 2.8 K to 923 (-66.81 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | M | 42.07 | 3,304 | 138,999 | 0 | |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | M | 38.76 | 2,434 | 94,342 | 0 | |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | M | 26.12 | 3,366 | 87,920 | 0 | |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | M | 41.19 | 3,632 | 149,602 | 0 | |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | M | 12.91 | 14,000 | 180,740 | 0 | |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Sell | S | 97.17 | 1,016 | 98,725 | 2,781 | 3.8 K to 2.8 K (-26.76 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Sell | S | 96.45 | 1,187 | 114,486 | 3,797 | 5 K to 3.8 K (-23.82 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Sell | S | 95.13 | 24,533 | 2,333,824 | 4,984 | 29.5 K to 5 K (-83.11 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Buy | M | 42.07 | 3,304 | 138,999 | 29,517 | 26.2 K to 29.5 K (+12.60 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Buy | M | 38.76 | 2,434 | 94,342 | 26,213 | 23.8 K to 26.2 K (+10.24 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Buy | M | 26.12 | 3,366 | 87,920 | 23,779 | 20.4 K to 23.8 K (+16.49 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Buy | M | 41.19 | 3,632 | 149,602 | 20,413 | 16.8 K to 20.4 K (+21.64 %) |
| Mar 20 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Buy | M | 12.91 | 14,000 | 180,740 | 16,781 | 2.8 K to 16.8 K (+503.42 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | M | 12.91 | 10,000 | 129,100 | 14,000 | |
| Mar 05 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Sell | S | 93.39 | 10,000 | 933,900 | 2,781 | 12.8 K to 2.8 K (-78.24 %) |
| Mar 05 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Buy | M | 12.91 | 10,000 | 129,100 | 12,781 | 2.8 K to 12.8 K (+359.58 %) |
| Feb 26 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Sell | S | 92.76 | 4,355 | 403,970 | 2,781 | 7.1 K to 2.8 K (-61.03 %) |
| Feb 26 2020 | RGEN | REPLIGEN CORP | Cox John | Director | Sell | S | 94.85 | 100 | 9,485 | 7,136 | 7.2 K to 7.1 K (-1.38 %) |
| May 17 2019 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | A | 67.71 | 2,109 | 142,800 | 2,109 | |
| May 17 2019 | RGEN | REPLIGEN CORP | Cox John | Director | Grant | A | 0.00 | 923 | 0 | 7,236 | 6.3 K to 7.2 K (+14.62 %) |
| May 17 2018 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | A | 42.07 | 3,304 | 138,999 | 3,304 | |
| May 17 2018 | RGEN | REPLIGEN CORP | Cox John | Director | Grant | A | 0.00 | 1,486 | 0 | 6,313 | 4.8 K to 6.3 K (+30.79 %) |
| Mar 08 2018 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | D | 44.51 | 193,683 | 8,620,830 | 0 | |
| Mar 08 2018 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | D | 44.51 | 387,366 | 17,241,661 | 0 | |
| Mar 08 2018 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | D | 7.82 | 48,230 | 377,159 | 0 | |
| Mar 08 2018 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | D | 0.00 | 48,678 | 0 | 0 | |
| Mar 08 2018 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | D | 0.00 | 136,364 | 0 | 0 | |
| Mar 08 2018 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Sell | D | 0.00 | 185,094 | 0 | 0 | 185.1 K to 0 (-100.00 %) |
| Feb 26 2018 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Payment of Exercise | F | 104.74 | 5,794 | 606,864 | 185,094 | 190.9 K to 185.1 K (-3.04 %) |
| Feb 26 2018 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Payment of Exercise | F | 104.30 | 13,973 | 1,457,384 | 190,888 | 204.9 K to 190.9 K (-6.82 %) |
| Feb 15 2018 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | M | 0.00 | 24,339 | 0 | 48,678 | |
| Feb 15 2018 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Payment of Exercise | F | 103.52 | 10,819 | 1,119,983 | 204,861 | 215.7 K to 204.9 K (-5.02 %) |
| Feb 15 2018 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Buy | M | 0.00 | 24,339 | 0 | 215,680 | 191.3 K to 215.7 K (+12.72 %) |
| Feb 13 2018 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | M | 9.53 | 18,381 | 175,171 | 0 | |
| Feb 13 2018 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Payment of Exercise | F | 103.05 | 7,672 | 790,600 | 191,341 | 199 K to 191.3 K (-3.86 %) |
| Feb 13 2018 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Buy | M | 9.53 | 18,381 | 175,171 | 199,013 | 180.6 K to 199 K (+10.18 %) |
| May 22 2017 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | A | 38.76 | 2,434 | 94,342 | 2,434 | |
| May 22 2017 | RGEN | REPLIGEN CORP | Cox John | Director | Grant | A | 0.00 | 1,206 | 0 | 4,827 | 3.6 K to 4.8 K (+33.31 %) |
| Apr 03 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Payment of Exercise | F | 54.46 | 8,416 | 458,335 | 180,632 | 189 K to 180.6 K (-4.45 %) |
| Mar 02 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | A | 9.53 | 18,381 | 175,171 | 18,381 | |
| Mar 02 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | A | 7.82 | 48,230 | 377,159 | 48,230 | |
| Mar 02 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Payment of Exercise | F | 43.42 | 6,726 | 292,043 | 189,048 | 195.8 K to 189 K (-3.44 %) |
| Mar 02 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Payment of Exercise | F | 47.76 | 6,436 | 307,383 | 195,774 | 202.2 K to 195.8 K (-3.18 %) |
| Mar 02 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Payment of Exercise | F | 49.56 | 2,641 | 130,888 | 202,210 | 204.9 K to 202.2 K (-1.29 %) |
| Mar 02 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Payment of Exercise | F | 43.42 | 6,986 | 303,332 | 204,851 | 211.8 K to 204.9 K (-3.30 %) |
| Mar 02 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Payment of Exercise | F | 47.76 | 8,355 | 399,035 | 211,837 | 220.2 K to 211.8 K (-3.79 %) |
| Mar 02 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Payment of Exercise | F | 49.56 | 3,383 | 167,661 | 220,192 | 223.6 K to 220.2 K (-1.51 %) |
| Mar 02 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Payment of Exercise | F | 43.42 | 3,404 | 147,802 | 223,575 | 227 K to 223.6 K (-1.50 %) |
| Mar 02 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Grant | A | 0.00 | 211,679 | 0 | 226,979 | 15.3 K to 227 K (+1,383.52 %) |
| Feb 16 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | A | 44.51 | 386,675 | 17,210,904 | 386,675 | |
| Feb 16 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | A | 44.51 | 193,337 | 8,605,430 | 193,337 | |
| Feb 16 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | A | 0.00 | 73,017 | 0 | 73,017 | |
| Feb 16 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | A | 44.51 | 386,675 | 17,210,904 | 386,675 | |
| Feb 16 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | A | 44.51 | 193,337 | 8,605,430 | 193,337 | |
| Feb 16 2017 | BIVV | Bioverativ Inc. | Cox John | Chief Executive Off ... | Option Exercise | A | 0.00 | 73,017 | 0 | 73,017 | |
| May 13 2016 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | A | 26.12 | 3,366 | 87,920 | 3,366 | |
| May 13 2016 | RGEN | REPLIGEN CORP | Cox John | Director | Grant | A | 0.00 | 1,763 | 0 | 3,621 | 1.9 K to 3.6 K (+94.89 %) |
| Apr 05 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Grant | A | 0.00 | 8,444 | 0 | 39,045 | 30.6 K to 39 K (+27.59 %) |
| Feb 25 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Option Exercise | J | 0.00 | 1,608 | 0 | 4,842 | |
| Feb 25 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Option Exercise | M | 0.00 | 810 | 0 | 6,450 | |
| Feb 25 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Payment of Exercise | F | 258.99 | 382 | 98,934 | 30,516 | 30.9 K to 30.5 K (-1.24 %) |
| Feb 25 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Buy | M | 0.00 | 810 | 0 | 30,898 | 30.1 K to 30.9 K (+2.69 %) |
| Feb 24 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Option Exercise | A | 0.00 | 11,850 | 0 | 11,850 | |
| Feb 17 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Option Exercise | J | 0.00 | 1,394 | 0 | 2,448 | |
| Feb 17 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Option Exercise | M | 0.00 | 2,246 | 0 | 2,249 | |
| Feb 17 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Option Exercise | M | 0.00 | 1,052 | 0 | 3,842 | |
| Feb 17 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Payment of Exercise | F | 247.22 | 1,057 | 261,312 | 30,088 | 31.1 K to 30.1 K (-3.39 %) |
| Feb 17 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Buy | M | 0.00 | 2,246 | 0 | 31,145 | 28.9 K to 31.1 K (+7.77 %) |
| Feb 17 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Payment of Exercise | F | 247.22 | 495 | 122,374 | 28,899 | 29.4 K to 28.9 K (-1.68 %) |
| Feb 17 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Buy | M | 0.00 | 1,052 | 0 | 29,394 | 28.3 K to 29.4 K (+3.71 %) |
| Feb 09 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Option Exercise | M | 0.00 | 4,026 | 0 | 0 | |
| Feb 09 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Payment of Exercise | F | 250.77 | 1,324 | 332,019 | 28,342 | 29.7 K to 28.3 K (-4.46 %) |
| Feb 09 2016 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Buy | M | 0.00 | 4,026 | 0 | 29,666 | 25.6 K to 29.7 K (+15.70 %) |
| May 26 2015 | RGEN | REPLIGEN CORP | Cox John | Director | Option Exercise | A | 41.19 | 3,632 | 149,602 | 3,632 | |
| May 26 2015 | RGEN | REPLIGEN CORP | Cox John | Director | Grant | A | 0.00 | 1,858 | 0 | 1,858 | 0 to 1.9 K |
| Mar 26 2015 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Option Exercise | M | 60.56 | 2,891 | 175,079 | 2,892 | |
| Mar 26 2015 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Option Exercise | M | 72.87 | 2,175 | 158,492 | 0 | |
| Mar 26 2015 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Sell | S | 449.06 | 12,010 | 5,393,211 | 25,567 | 37.6 K to 25.6 K (-31.96 %) |
| Mar 26 2015 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Buy | M | 60.56 | 2,891 | 175,079 | 37,577 | 34.7 K to 37.6 K (+8.33 %) |
| Mar 26 2015 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Buy | M | 72.87 | 2,175 | 158,492 | 34,686 | 32.5 K to 34.7 K (+6.69 %) |
| Feb 25 2015 | IDPH | BIOGEN INC. | Cox John | EVP Pharmaceutical ... | Option Exercise | A | 0.00 | 7,260 | 0 | 7,260 |
Page: 1